New Zealand medicinal cannabis company Helius Therapeutics has entered into an exclusive partnership with healthcare and pharmaceutical consulting firm Datapharm to deliver prescriber education programs and resources.

The new information service – MCinfo.com – launched this week with Helius as its education sponsor. Datapharm will deliver in-person programs nationwide alongside an online information platform.

Dubbed New Zealand’s medicinal cannabinoid information service, MCinfo.com is available to patients and the public, with registration free for doctors, nurses, and pharmacists.

Helius Therapeutics chief executive Carmen Doran

Helius Therapeutics chief executive Carmen Doran said: “We know enhancing prescriber knowledge is key to ensuring greater patient access to medicinal cannabis.”

According to a survey by Horizon Research, 76% of healthcare professionals in New Zealand reported a need to be better informed about cannabinoid medicines and how to prescribe them.

Datapharm has worked closely with the medicinal cannabis sector for the past three years, with director Mark Morrison consulting to Helius since 2020 before being appointed its chief commercial officer earlier this year.

Doran added: “There has been a vacuum of information in the medicinal cannabis space which our exclusive partnership with Datapharm now comprehensively fills. It’s an exciting development for the industry and, most importantly, patients.”

Helius has now completed its integrated medicines manufacturing facility in Auckland’s East Tamaki, having raised NZ$48 million since 2018.